Skip to content
Health
Link copied to clipboard
Link copied to clipboard

A Navy Yard biotech designed a first-of-its-kind therapy for rare cancer. Now, it waits for patients.

The first patient blood samples, just weeks away, will open a new chapter in medicine’s ongoing search for a therapy that converts the body’s own immune system to a cancer-killing machine.

Dennis Williams (left), Senior Vice President, Late Stage Development and Mark Stielow (right), Vice President U.S. Manufacturing and Technical Operations at Adaptimmune in the Navy Shipyard, Thursday, Sept. 12, 2024. After getting approval for a new type of cancer therapy (Tecelra) that uses the immune system to target cancer cells, the company is gearing up for patient orders to arrive.
Dennis Williams (left), Senior Vice President, Late Stage Development and Mark Stielow (right), Vice President U.S. Manufacturing and Technical Operations at Adaptimmune in the Navy Shipyard, Thursday, Sept. 12, 2024. After getting approval for a new type of cancer therapy (Tecelra) that uses the immune system to target cancer cells, the company is gearing up for patient orders to arrive.Read moreAlejandro A. Alvarez / Staff Photographer